Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.

Publication ,  Journal Article
Sanchez-Perez, L; Choi, BD; Reap, EA; Sayour, EJ; Norberg, P; Schmittling, RJ; Archer, GE; Herndon, JE; Mitchell, DA; Heimberger, AB ...
Published in: Cancer Immunol Immunother
June 2013

B lymphocyte stimulator (BLyS) is a cytokine involved in differentiation and survival of follicular B cells along with humoral response potentiation. Lymphopenia is known to precipitate dramatic elevation in serum BLyS; however, the use of this effect to enhance humoral responses following vaccination has not been evaluated. We evaluated BLyS serum levels and antigen-specific antibody titers in 8 patients undergoing therapeutic temozolomide (TMZ)-induced lymphopenia, with concomitant vaccine against a tumor-specific mutation in the epidermal growth factor receptor (EGFRvIII). Our studies demonstrate that TMZ-induced lymphopenia corresponded with spikes in serum BLyS that directly preceded the induction of anti-EGFRvIII antigen-specific antibody titers, in some cases as high as 1:2,000,000. Our data are the first clinical observation of BLyS serum elevation and greatly enhanced humoral immune responses as a consequence of chemotherapy-induced lymphopenia. These observations should be considered for the development of future vaccination strategies in the setting of malignancy.

Duke Scholars

Published In

Cancer Immunol Immunother

DOI

EISSN

1432-0851

Publication Date

June 2013

Volume

62

Issue

6

Start / End Page

983 / 987

Location

Germany

Related Subject Headings

  • Temozolomide
  • Lymphopenia
  • Lymphocyte Depletion
  • Immunology
  • Humans
  • Glioblastoma
  • Dacarbazine
  • Cancer Vaccines
  • B-Cell Activating Factor
  • Antineoplastic Agents, Alkylating
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sanchez-Perez, L., Choi, B. D., Reap, E. A., Sayour, E. J., Norberg, P., Schmittling, R. J., … Sampson, J. H. (2013). BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunol Immunother, 62(6), 983–987. https://doi.org/10.1007/s00262-013-1405-y
Sanchez-Perez, Luis, Bryan D. Choi, Elizabeth A. Reap, Elias J. Sayour, Pamela Norberg, Robert J. Schmittling, Gerald E. Archer, et al. “BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.Cancer Immunol Immunother 62, no. 6 (June 2013): 983–87. https://doi.org/10.1007/s00262-013-1405-y.
Sanchez-Perez L, Choi BD, Reap EA, Sayour EJ, Norberg P, Schmittling RJ, et al. BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunol Immunother. 2013 Jun;62(6):983–7.
Sanchez-Perez, Luis, et al. “BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.Cancer Immunol Immunother, vol. 62, no. 6, June 2013, pp. 983–87. Pubmed, doi:10.1007/s00262-013-1405-y.
Sanchez-Perez L, Choi BD, Reap EA, Sayour EJ, Norberg P, Schmittling RJ, Archer GE, Herndon JE, Mitchell DA, Heimberger AB, Bigner DD, Sampson JH. BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunol Immunother. 2013 Jun;62(6):983–987.
Journal cover image

Published In

Cancer Immunol Immunother

DOI

EISSN

1432-0851

Publication Date

June 2013

Volume

62

Issue

6

Start / End Page

983 / 987

Location

Germany

Related Subject Headings

  • Temozolomide
  • Lymphopenia
  • Lymphocyte Depletion
  • Immunology
  • Humans
  • Glioblastoma
  • Dacarbazine
  • Cancer Vaccines
  • B-Cell Activating Factor
  • Antineoplastic Agents, Alkylating